Acta Scientific Gastrointestinal Disorders (ISSN: 2582-1091)

Case ReportVolume 4 Issue 6

Terlipressin Induced Reversible Valvular Dysfunction in a Cirrhotic Patient for Living Donor Liver Transplant: Case Report

Manoj Gupta* and K R Vasudevan

Department of Liver Transplant and Surgical Gastroenterology, PSRI Hospital, New Delhi, India

*Corresponding Author: Manoj Gupta, Department of Liver Transplant and Surgical Gastroenterology, PSRI Hospital, New Delhi, India.

Received: June 07, 2021; Published: July 13, 2021

Citation: Manoj Gupta and K R Vasudevan. “Terlipressin Induced Reversible Valvular Dysfunction in a Cirrhotic Patient for Living Donor Liver Transplant: Case Report". Acta Scientific Gastrointestinal Disorders 4.8 (2021): 23-25.

Abstract

Terlipressin, a vasopressin analogue, has known cardiac side effects e.g. arrhythmias, reduced left ventricular ejection fraction, non ST elevation myocardial infarction. However, to the best of our knowledge reversible valvular insufficiency with pulmonary hypertension with terlipressin has never been described in the literature in cirrhotics. As in the present case it was reversible therefore definitive treatment i.e. liver transplantation should not be deferred in this subgroup of patients.

 

Keywords: Terlipressin; Arginine Vasopressin; Myocardial Infarction; Arrhythmias

Bibliography

  1. Ioannou G., et al. “Terlipressin for acute oesophageal variceal haemorrhage”. Cochrane Database of Systematic Reviews 1 (2003): CD002147.
  2. Moreau R and Lebrec D. “The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond”. Hepatology 43 (2006): 385-394.
  3. Salerno F., et al. “Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis”. Gut 56 (2007): 1310-1318.
  4. Krag A., et al. “Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome”. Advances in Therapy 25 (2008): 1105-1140.
  5. Rosario R., et al. “Myocardial infarction after injection of terlipressin for digestive hemorrhage”. Gastroentérologie Clinique et Biologique 20 (1996): 712-713.
  6. Lee MY., et al. “Terlipressin-related acute myocardial infarction: a case report and literature review”. Kaohsiung Journal of Medical Sciences 20 (2004): 604-608.
  7. Elzouki Abdul-Naser., et al. “Terlipressin-induced severe left and right ventricular dysfunction in patient presented with upper gastrointestinal bleeding: case report and literature review”. American Journal of Emergency Medicine 28 (2010): 540.e1-540.e6.
  8. Aleksander Krag., et al. “Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis”. European Journal of Gastroenterology and Hepatology9 (2010).
  9. Altintas E., et al. “Effects of terlipressin on systolic pulmonary artery pressure of patients with liver cirrhosis”. World Journal of Gastroenterology 10 (2004): 2278-2280.

Copyright: © Manoj Gupta and K R Vasudevan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 05, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US